Journal article

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)

PK Ellegaard, RW Licht, HE Poulsen, RE Nielsen, M Berk, OM Dean, M Mohebbi, CT Nielsen

International Journal of Bipolar Disorders | SPRINGER | Published : 2018

Abstract

Background: Oxidative stress and inflammation may be involved in the development and progression of mood disorders, including bipolar disorder. Currently, there is a scarcity of useful treatment options for bipolar depressive episodes, especially compared with the efficacy of treatment for acute mania. N-Acetylcysteine (NAC) has been explored for psychiatric disorders for some time given its antioxidant and anti-inflammatory properties. The current trial aims at testing the clinical effects of adjunctive NAC treatment (compared to placebo) for bipolar depression. We will also explore the biological effects of NAC in this context. We hypothesize that adjunctive NAC treatment will reduce sympt..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Brain and Behavior Research Foundation


Funding Acknowledgements

The trial has received grants from: The Psychiatry Research Foundation in Region of Southern Denmark, Ph.D. Scholarship from The University of Southern Denmark, Mental Health Service, Vejle and Beckett Foundation. All grants were unrestricted with respect to the development or execution of the trial, study design, analysis plan and dissemination of study results.